AXEVIL Capital

Orca Bio Stock Price, Valuation & IPO

Private company — Orca Bio is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.

Status source: AXEVIL investment team

$51.84 per share (AXEVIL consensus estimate)

Source: AXEVIL consensus of recent secondary transactions · as of 17 November 2026

Last round valuation: $2.4B

Source: F, January 2026, post-money

Total raised: ~$550M

Data last updated: 17 November 2026

About Orca Bio

Orca Bio was founded in 2016 in Menlo Park by Ivan Dimov, Nate Fernhoff, and Jeroen Bekart; the company grew out of Irving Weissman's Stanford laboratory, and its technologies are exclusively licensed from Stanford. After a bone marrow transplant from a donor, new immune cells often attack the patient's organs, and treatment for these complications can last for years. Orca Bio's platform analyzes donor cells individually and assembles a personalized transplant where regulatory T-cells curb such an attack. In the Phase 3 Precision-T trial involving 187 patients, 78% lived without chronic complications after one year, compared to 38% with a standard transplant; survival rate was 94% versus 83%. On June 30, 2026, the FDA approved the drug Tregzi, with a wholesale course price of $428 thousand. A total of approximately $550 million has been raised.

  • Sector: Health & Pharma

Key highlights

  1. Stanford: technology and main publication. The platform is exclusively licensed from Stanford, where the founders worked in the Weismann Lab. The lead author of the Phase 3 article in the journal Blood was Everett Meyer from Stanford.
  2. UCLA: survival confirmed at three years. Caspian Oliai from the UCLA transplant center co-authored an analysis comparing 76 patients with Tregzi and 360 patients from the CIBMTR registry. After three years, 83% and 66% were alive, respectively; the work was published in September 2026.
  3. Kaiser Permanente: hospital network became a shareholder. In the 2020 Series D round, Kaiser Foundation Hospitals and the Kaiser Permanente pension fund participated — one of the largest hospital systems in the US invested six years before product approval.

Funding rounds

DateRoundPrice / sharePost-money valuation
9 January 2026F$54.99$2.4B
17 June 2020D$35.01$1.1B

Frequently asked questions

How can I buy Orca Bio stock before the IPO?

Not on a public exchange — Orca Bio is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.

What is the Orca Bio stock price?

A private company has no single official share price. AXEVIL's consensus estimate is $51.84 per share as of 17 November 2026. Its most recent round implied a post-money valuation of $2.4B (January 2026).

What is Orca Bio's valuation (net worth)?

Orca Bio's most recent funding round valued the company at $2.4B post-money (January 2026) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.

When will Orca Bio IPO?

No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.

Is Orca Bio publicly traded?

No. Orca Bio is a private company and its shares are not listed on any public exchange.

Does Orca Bio have a stock symbol?

No. Orca Bio has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.

Similar companies

Risk disclosure

Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.

Full legal disclosures · All companies